A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.
about
Vaccines against tuberculosis: where are we and where do we need to go?Crystallographic and Spectroscopic Insights into Heme Degradation by Mycobacterium tuberculosis MhuDDiscovery and characterization of a unique mycobacterial heme acquisition systemCurrent efforts and future prospects in the development of live mycobacteria as vaccinesTuberculosis vaccines: barriers and prospects on the quest for a transformative toolPriming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cellsRecombinant Mycobacterium bovis BCG as an HIV vaccine vector.Mycobacterium tuberculosis Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) Functions as a Receptor for Human Lactoferrin.A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis chalrBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.New approaches in the diagnosis and treatment of latent tuberculosis infectionMycobacterium tuberculosis acquires iron by cell-surface sequestration and internalization of human holo-transferrin.A new recombinant BCG vaccine induces specific Th17 and Th1 effector cells with higher protective efficacy against tuberculosis.Priming with recombinant auxotrophic BCG expressing HIV-1 Gag, RT and Gp120 and boosting with recombinant MVA induces a robust T cell response in mice.The ESX-3 secretion system is necessary for iron and zinc homeostasis in Mycobacterium tuberculosis.Characterization of heme ligation properties of Rv0203, a secreted heme binding protein involved in Mycobacterium tuberculosis heme uptake.Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence.Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoireBoosting BCG to protect against TB.Biosynthesis of mycobacterial lipids by polyketide synthases and beyond.Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting MemoryA kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli.Mutational and phylogenetic analyses of the mycobacterial mbt gene cluster.Disruption of mycobactin biosynthesis leads to attenuation of Mycobacterium tuberculosis for growth and virulence.Listeria-vectored vaccine expressing the Mycobacterium tuberculosis 30 kDa major secretory protein via the constitutively active prfA* regulon boosts BCG efficacy against tuberculosis.Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.Computational Identification and Characterization of a Promiscuous T-Cell Epitope on the Extracellular Protein 85B of Mycobacterium spp. for Peptide-Based Subunit Vaccine DesignNext-Generation Vaccines Based on Bacille Calmette-Guérin.
P2860
Q26992233-5102CFDF-DD61-4DD6-A44E-1A3F5D855194Q27644563-CEB85FF8-E214-45CF-8104-72DC2DD9EB0DQ27667213-1C163BD6-1282-4BEA-8BB0-90BE78D75CCDQ28087077-9FD3D407-1FDB-4653-98A9-F2DB4EA435DEQ28390218-32A489C7-68F7-4E1F-94EB-6E7B4759DA8AQ28730854-2BA31767-2E0C-4B60-A77B-45610727FCDCQ30387447-199CFD49-44F1-4FE2-AAB4-451999230FFBQ33774924-C6CCAAF1-8918-4983-9BC2-7AA7B9C46FBDQ34177350-C6B91315-0426-4C8B-86B9-545718D9A74CQ34298426-A8079755-2DB1-4417-9084-FF129964435EQ34419185-DFD0724B-D3C8-4BFF-B314-10603A840B77Q34435468-DD82E9C1-0C14-4547-9A05-7C972D022BDDQ34513982-DCDF856A-EE74-4742-97C2-5745D3C3A5A2Q34971570-BD4629D1-B207-4FA4-AAA7-5F63BCA10DFBQ35025557-69A97E31-0201-4ACE-A818-6E965339D7B3Q35822908-6368CB90-7653-4699-9DBE-91C02BA5002EQ36498319-FCD460B7-8BEA-4E85-801C-12CC563964C1Q36759963-D7082D84-8FA1-4F9C-A59A-BD6C0702559EQ37337116-84CCB3E4-63AF-428A-AE38-6404E9919F01Q37374704-FE0E1851-0608-4A9E-9E7B-09EEA934C596Q37762830-1C859667-2321-417D-BD42-56B0EF8844F6Q38195645-744E0F39-70D9-4285-951F-40CA480141F6Q38207991-8CD0D5FF-9AC0-414F-8A98-D58A4BA61FB7Q38364440-28BF52B6-39C5-4138-A786-8DE405CFFC42Q38725050-97AB792E-C0A7-4BAB-9C30-D61EED79F0F5Q39136936-E99E4DC8-23EB-4073-9406-F738CA991BB3Q40166395-0C338806-99B7-4448-BFA0-5920530F2EEAQ40557637-A407D048-F890-422E-96CF-86AEB8971F24Q42177811-C91E605F-420D-4EE4-B9BA-43C1545C9E84Q49829375-869E15BE-37F0-4C50-8CF8-A00AE2D886BF
P2860
A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A Replication-Limited Recombin ...... and more efficacious than BCG.
@en
type
label
A Replication-Limited Recombin ...... and more efficacious than BCG.
@en
prefLabel
A Replication-Limited Recombin ...... and more efficacious than BCG.
@en
P2093
P2860
P356
P1476
A Replication-Limited Recombin ...... and more efficacious than BCG.
@en
P2093
Barbara J Dillon
Günter Harth
Marcus A Horwitz
Michael V Tullius
Sasa Maslesa-Galic
P2860
P304
P356
10.1128/IAI.00434-08
P407
P577
2008-08-25T00:00:00Z